RecruitingNCT06212947
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
Studying Hypochondroplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Principal Investigator
- Medical Director, MD, MDBioMarin Pharmaceutical
- Enrollment
- 400 target
- Eligibility
- 15 years · All sexes
- Timeline
- 2023 – 2043
Study locations (30)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- UCSF Benioff Children's Hospital, Oakland, California, United States
- Nemours Alfred I. Dupont Hospital for Children, Wilmington, Delaware, United States
- Children's National Health System, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, United States
- University of Missouri, Columbia, Missouri, United States
- Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
- Mount Sinai Kravis Children's Hospital, New York, New York, United States
- Akron Children's Hospital, Akron, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Cook Children's Endocrinology, Fort Worth, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06212947 on ClinicalTrials.govOther trials for Hypochondroplasia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07393373Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- RECRUITINGPHASE2NCT07126262A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsBioMarin Pharmaceutical
- ENROLLING BY INVITATIONPHASE3NCT07073014Long-Term Extension Study of Vosoritide to Treat Children With HypochondroplasiaBioMarin Pharmaceutical
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT06873035An Interventional Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company
- ACTIVE NOT RECRUITINGPHASE3NCT06455059Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaBioMarin Pharmaceutical
- RECRUITINGNCT06410976Prospective Clinical Assessment Study in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company